Clinical Trial: Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain

This study has been completed.

Sponsored by: Dana-Farber/Harvard Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain. PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled morphine with that of morphine given by mouth in treating cancer patients who have breakthrough pain.

Condition Treatment or Intervention Phase
Pain
unspecified adult solid tumor, protocol specific
Quality of Life
 Drug: morphine
Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy;   Pain

Study Type: Interventional
Study Design: Educational/Counseling/Training

Official Title: Phase II Randomized Study of Aerosolized Versus Oral Morphine Sulfate in Cancer Patients With Opioid-Sensitive Breakthrough Pain

Further Study Details: 

Study start: March 2001

OBJECTIVES: I. Compare the change in pain intensity during the 15 minutes immediately following aerosolized vs oral morphine sulfate in cancer patients with opioid-sensitive breakthrough pain. II. Compare preference for continued use of these regimens in these patients. III. Compare the pain relief in patients treated with these regimens. IV. Evaluate satisfaction of patients treated with these regimens.

PROTOCOL OUTLINE: This is a randomized, open-label, crossover, multicenter study. Patients are randomized to 1 of 2 treatment arms. Patients undergo titration of aerosolized morphine sulfate over days 1-7 to determine the optimal baseline and breakthrough dosage. Arm I: Patients receive aerosolized morphine sulfate as needed for breakthrough pain, up to 4 inhalations every 15 minutes, on days 8-14. Patients crossover to oral morphine sulfate as needed for breakthrough pain on days 15-21. Arm II: Patients receive oral morphine sulfate as needed for breakthrough pain on days 8-14. Patients crossover to aerosolized morphine sulfate as needed for breakthrough pain, up to 4 inhalations every 15 minutes, on days 15-21. Patients may continue treatment with either oral or aerosolized morphine sulfate for an additional 60 days beginning on day 22. Quality of life is assessed weekly for 3 weeks. Patients complete a pain management satisfaction survey at the end of each therapy crossover week.

PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: Recovered from prior chemotherapy; No concurrent chemotherapy that would cause toxicity (e.g., emesis)
  • Endocrine therapy: Not specified
  • Radiotherapy: Recovered from prior radiotherapy; No concurrent radiotherapy that would cause toxicity (e.g., emesis)
  • Surgery: Not specified
  • Other: At least 30 days or 5 half-lives (whichever is longer) since prior investigational drug; No concurrent MAO inhibitors

--Patient Characteristics--

  • Age: 18 and over
  • Performance status: ECOG 0-3
  • Life expectancy: More than 3 months
  • Hematopoietic: Not specified
  • Hepatic: Bilirubin less than 2.0 mg/dL; AST less than 82 U/L; ALT less than 72 U/L
  • Renal: Creatinine less than 1.5 mg/dL
  • Pulmonary: No significant history or recent exacerbation of bronchial asthma; No chronic obstructive pulmonary disease; No significant pulmonary pathology that would preclude study
  • Other: No history of substance abuse, including alcohol, within the past 2 months; No other condition that would preclude study; Not pregnant or nursing; Fertile patients must use effective contraception

Location Information


Massachusetts
      Brigham and Women's Hospital, Boston,  Massachusetts,  02115,  United States

Study chairs or principal investigators

Nathaniel Katz,  Study Chair,  Dana-Farber/Harvard Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000068672; DFCI-MOR-00-01; ARADIGM-MOR-00-01; BWH-2000-P-001516
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  July 11, 2001
ClinicalTrials.gov Identifier:  NCT00020618
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources